Literature DB >> 25225421

Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease.

Sivaramakrishna P Rachakonda1, Olaf Penack1, Sascha Dietrich1, Olga Blau1, Igor Wolfgang Blau1, Aleksandar Radujkovic1, Berend Isermann1, Anthony D Ho1, Lutz Uharek1, Peter Dreger1, Rajiv Kumar1, Thomas Luft2.   

Abstract

PURPOSE: Steroid-refractory graft-versus-host disease (GVHD) is a major and often fatal complication after allogeneic stem-cell transplantation (alloSCT). Although the pathophysiology of steroid refractoriness is not fully understood, evidence is accumulating that endothelial cell stress is involved, and endothelial thrombomodulin (THBD) plays a role in this process. Here we assess whether single-nucleotide polymorphisms (SNPs) within the THBD gene predict outcome after alloSCT. PATIENTS AND METHODS: Seven SNPs within the THBD gene were studied (rs1962, rs1042579, rs1042580, rs3176123, rs3176124, rs3176126, and rs3176134) in a training cohort of 306 patients. The relevant genotypes were then validated in an independent cohort (n = 321).
RESULTS: In the training cohort, an increased risk of nonrelapse mortality (NRM) was associated with three of seven SNPs tested: rs1962, rs1042579 (in linkage disequilibrium with rs3176123), and rs1042580. When patients were divided into risk groups (one v no high-risk SNP), a strong correlation with NRM was observed (hazard ratio [HR], 2.31; 95% CI, 1.36 to 3.95; P = .002). More specifically, NRM was predicted by THBD SNPs in patients who later developed GVHD (HR, 3.03; 95% CI, 1.61 to 5.68; P < .001) but not in patients without GVHD. In contrast, THBD SNPs did not predict incidence of acute GVHD. Multivariable analyses adjusting for clinical variables confirmed the independent effect of THBD SNPs on NRM. All findings could be reproduced in the validation cohort.
CONCLUSION: THBD SNPs predict mortality of manifest GVHD but not the risk of acquiring GVHD, supporting the hypothesis that endothelial vulnerability contributes to GVHD refractoriness.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25225421     DOI: 10.1200/JCO.2013.54.4056

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

1.  Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Case-Control and Family-Based Studies in Multiethnic Populations.

Authors:  Priyanka Nakka; Natalie P Archer; Heng Xu; Philip J Lupo; Benjamin J Raphael; Jun J Yang; Sohini Ramachandran
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

2.  Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Authors:  Shernan G Holtan; Michael R Verneris; Kirk R Schultz; Laura F Newell; Gabrielle Meyers; Fiona He; Todd E DeFor; Gregory M Vercellotti; Arne Slungaard; Margaret L MacMillan; Sarah A Cooley; Bruce R Blazar; Angela Panoskaltsis-Mortari; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-07       Impact factor: 5.742

3.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Authors:  Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

4.  Endothelial damage is aggravated in acute GvHD and could predict its development.

Authors:  E Mir; M Palomo; M Rovira; A Pereira; G Escolar; O Penack; E Holler; E Carreras; M Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

5.  Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.

Authors:  M Zeisbrich; N Becker; A Benner; A Radujkovic; K Schmitt; J Beimler; A D Ho; M Zeier; P Dreger; T Luft
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

6.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

7.  A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.

Authors:  Haruka Nomoto; Akiyoshi Takami; J Luis Espinoza; Keitaro Matsuo; Shohei Mizuno; Makoto Onizuka; Koichi Kashiwase; Yasuo Morishima; Takahiro Fukuda; Yoshihisa Kodera; Noriko Doki; Koichi Miyamura; Takehiko Mori; Shinji Nakao; Shigeki Ohtake; Eriko Morishita
Journal:  Int J Hematol       Date:  2015-08-06       Impact factor: 2.490

8.  Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.

Authors:  Sonata Jodele; Tsuyoshi Fukuda; Kana Mizuno; Alexander A Vinks; Benjamin L Laskin; Jens Goebel; Bradley P Dixon; Ranjit S Chima; Russel Hirsch; Ashley Teusink; Danielle Lazear; Adam Lane; Kasiani C Myers; Christopher E Dandoy; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-09       Impact factor: 5.742

9.  Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Laura F Newell; Todd E DeFor; Corey Cutler; Michael R Verneris; Bruce R Blazar; Jeff S Miller; Joseph H Antin; Alan Howard; Juan Wu; Margaret L MacMillan; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Shernan G Holtan
Journal:  Biol Blood Marrow Transplant       Date:  2019-11-10       Impact factor: 5.742

Review 10.  A risk-adapted approach to acute GVHD treatment: are we there yet?

Authors:  S G Holtan; M L MacMillan
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.